Jeena Sikho Lifecare logo

Jeena Sikho Lifecare

JSLL NSE

Key Fundamentals

MicrocapPharmaceuticalsHealthcare
Market Cap
₹6,329 Cr
Volatility
Moderate
P/E Ratio
26.9
EBITDA
₹349 Cr
Return on Equity
26.65%
Debt to Equity
0.27
Book Value
₹37.58
52W High
₹849.5
52W Low
₹492

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

5
  • Company is expected to give good quarter
  • Company has delivered good profit growth of 84.5% CAGR over last 5 years
  • Company has a good return on equity (ROE) track record: 3 Years ROE 49.6%
  • Company has been maintaining a healthy dividend payout of 19.1%
  • Debtor days have improved from 51.4 to 31.8 days.

Weaknesses

1
  • Stock is trading at 13.6 times its book value

Growth Rate

Revenue Growth
287% higher than 3Y
Net Income Growth
548% higher than 3Y
Cash Flow Change
-11.19% lower than 3Y
ROE
-13.14% lower than 3Y
ROCE
-17.44% level than 3Y
EBITDA Margin (Avg.)
85.59% lower than 3Y

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 69d ago
AI opinion · based on fundamentals
Risk high

Jeena Sikho Lifecare Ltd is a Rs 7,181 Cr market cap company that has delivered exceptional profit growth of 85% CAGR over 5 years and TTM sales growth of 71%, while trading at a P/B of 15.3x and P/E of 32.3x. The company maintains a 3-year average ROE of approximately 50%, indicating high capital efficiency, though its premium valuation leaves limited margin of safety.

Bull Case 8
  • Compounded profit growth of 85% CAGR over 5 years demonstrates sustained earnings momentum far exceeding sector averages
  • TTM sales growth of 71% indicates strong revenue acceleration and expanding market reach
  • 3-year ROE of 50% and last year ROE of 60% reflect exceptional capital efficiency and profitability
  • Debtor days improved from 51.4 to 31.8 days, signaling better working capital management and faster cash conversion
  • 3-year compounded sales CAGR of 58% shows consistent top-line scaling over a meaningful period
  • Healthy dividend payout ratio of 19.1% with 0.19% yield shows willingness to return capital to shareholders even during high-growth phase
  • TTM profit growth of 152% suggests a significant step-up in earnings trajectory in the most recent period
  • Stock CAGR of 116% over 3 years reflects market recognition of the company's growth execution
Bear Case 8
  • P/B ratio of 15.3x is extremely elevated, pricing in substantial future growth and leaving little room for disappointment
  • P/E of 32.3x is a premium multiple that requires continued high earnings growth to justify current valuation
  • No 52-week high/low data available (reported as 0), limiting ability to assess recent price volatility and technical support levels
  • Absence of reported debt-to-equity ratio creates uncertainty around the company's leverage and financial risk profile
  • Limited long-term track record with no 10-year sales or profit CAGR data available, making it difficult to assess durability through full market cycles
  • Dividend yield of only 0.19% provides negligible income cushion for investors if growth decelerates
  • At Rs 7,181 Cr market cap with 85% profit CAGR, sustaining such growth rates becomes mathematically harder as the base expands, creating mean-reversion risk
  • Consumer discretionary sector classification exposes the company to demand cyclicality and discretionary spending slowdowns during economic downturns

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 69d ago
Positives 4
  • Research institute MoU signed Jun 15

    JSLL signed a five-year MoU to establish a research institute in Chandigarh focused on Ayurveda and integrative healthcare, strengthening R&D capabilities.

  • New 160+ bed Lucknow hospital Jun 12

    Proposed 160+ bed hospital in Lucknow spanning ~1.25 lakh sq. ft. with operations commencing August 2026, funded internally at ~₹3 Cr investment.

  • 100-bed Mathura hospital operational Jun 10

    Sanskriti Ayurvedic P.G. Medical College & Hospital commenced operations on June 10 with 100 beds across 60,000 sq. ft. and OPD capacity of 8.

  • Ayodhya day care clinic planned Jun 11

    New Day Care Clinic in Ayodhya to be operational by August 2026 with ₹50 Lakh investment, expanding UP footprint.

Neutral 3
  • Land sale with lease-back ₹9.05 Cr Jun 19

    Board approved sale of Punjab land and building to VSB Enterprises for ₹9.05 Cr; operations continue via lease-back arrangement.

  • GIA conference participation Jun 23 Jun 17

    Management to attend GIA Flagship Conference on June 23, 2026 in Mumbai for a physical group meeting with analysts.

  • Virtual investor meet Jun 12 Jun 9

    Investor/analyst meet held on June 12, 2026, organized virtually by Choice Institutional Equities.

TL;DR: JSLL is in aggressive expansion mode, opening new hospitals and clinics across UP (Mathura, Lucknow, Ayodhya) while investing in Ayurveda research via a Chandigarh institute. No material headwinds are visible; the ₹9.05 Cr asset sale with lease-back provides liquidity without disrupting operations. The expansion trend is clearly accelerating with multiple facilities targeting August 2026 commencement, though investors should monitor execution risk across simultaneous projects.

Quarterly Results

Particulars Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
100
114
116
139
174
190
222
216
224
Expenses
75
74
86
93
96
98
121
138
132
Operating Profit
25
40
30
46
79
92
101
78
92
OPM %
25%
35%
26%
33%
45%
48%
45%
36%
41%
Other Income
3
3
0
0
1
1
3
4
14
Interest
1
2
4
3
2
4
3
4
3
Depreciation
5
6
8
9
10
10
11
16
15
PBT
21
35
18
34
69
79
89
62
87
Tax %
23%
25%
26%
25%
25%
25%
25%
26%
25%
Net Profit
16
27
13
25
51
59
67
45
66
EPS in Rs
1.3
2.14
1.06
2.04
4.13
4.73
5.37
3.65
5.28
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
106
94
136
146
204
324
469
801
851
Expenses
95
84
119
128
158
231
344
452
488
Operating Profit
11
11
17
18
46
93
125
350
363
OPM %
10%
11%
13%
12%
23%
29%
27%
44%
43%
Other Income
0
1
1
1
2
6
6
9
22
Interest
1
2
1
1
1
0
1
13
15
Depreciation
1
2
2
3
3
5
9
48
53
PBT
8
8
14
15
45
94
122
298
317
Tax %
28%
26%
27%
26%
24%
26%
26%
25%
—
Net Profit
6
6
10
11
34
69
91
222
237
EPS in Rs
66.67
63.67
93.55
1.24
2.71
5.57
7.3
17.87
19.03
Div. Payout %
0%
0%
0%
0%
8%
17%
15%
25%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
0.1
0.1
0.1
10
14
25
25
25
Reserves
8
14
24
26
112
167
248
443
Borrowings
16
12
12
7
1
1
11
127
Other Liabilities
12
12
13
18
24
28
45
78
Total Liabilities
36
38
49
62
151
221
328
673
Fixed Assets
13
17
23
28
60
67
153
307
CWIP
0
0
0
5
1
4
13
2
Investments
0
0
0
0
5
4
4
95
Other Assets
23
21
26
28
86
146
159
269
Total Assets
36
38
49
62
151
221
328
673
Figures in ₹ Crores

Cash Flow

Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
1
12
18
17
17
37
69
262
Investing
-11
-6
-8
-20
-57
-18
-70
-211
Financing
7
-5
-2
-5
48
-3
-1
-59
Net Cash Flow
-2
1
8
-7
8
15
-2
-8
Free Cash Flow
-10
6
9
-1
-13
23
-40
231
CFO/OP
35
130
125
118
55
66
81
96
Figures in ₹ Crores

Ratios

Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
15
17
9
22
40
46
76
32
Inventory Days
204
315
208
136
87
121
135
80
Days Payable
125
168
73
109
129
75
111
86
Cash Conversion Cycle
94
163
143
49
-2
92
100
26
Working Capital Days
-16
-15
-19
-11
29
58
55
54
ROCE %
—
38%
50%
39%
53%
58%
50%
71%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Jeena Sikho Lifecare insights

58 extracted metrics + investor summaries across FY19–FY26.

Log in — free

Shareholding Pattern

DIIs0.36%Promot.63.62%FIIs4.78%Others10.22%Public21.02%As ofJun 2026

Documents

Frequently Asked Questions about Jeena Sikho Lifecare

What does Jeena Sikho Lifecare Ltd do?
Jeena Sikho Lifecare is one of the leading ayurvedic healthcare system providers in India. The company is providing healthcare services for the last ten years.
Where is Jeena Sikho Lifecare Ltd (JSLL) listed?
Jeena Sikho Lifecare Ltd trades as JSLL on the NSE and under code 544476 on the BSE.
Which sector does Jeena Sikho Lifecare Ltd belong to?
Jeena Sikho Lifecare Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Jeena Sikho Lifecare Ltd?
Jeena Sikho Lifecare Ltd has a market capitalisation of ₹6,329 Cr, which places it in the Mid Cap band.
What is the PE ratio of Jeena Sikho Lifecare Ltd?
Jeena Sikho Lifecare Ltd trades at a PE ratio of 26.90, against a book value of ₹37.58 per share.
What is the 52-week high and low of Jeena Sikho Lifecare Ltd?
Over the last 52 weeks Jeena Sikho Lifecare Ltd has traded between ₹492 and ₹849.5.
Does Jeena Sikho Lifecare Ltd pay dividends?
Jeena Sikho Lifecare Ltd has a dividend yield of 0.87%.
What is the Return on Equity (ROE) of Jeena Sikho Lifecare Ltd?
Jeena Sikho Lifecare Ltd reported a return on equity of 26.65%. Its debt-to-equity ratio is 0.27.

Company Information

Jeena Sikho Lifecare is one of the leading ayurvedic healthcare system providers in India. The company is providing healthcare services for the last ten years.

Website jeenasikho.com
Listed 2025-08-11
Face Value ₹ 2
Issued Size 12,43,00,730

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/JSLL.md for Jeena Sikho Lifecare Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List